Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2017

View Archived Issues

TG Therapeutics reports outcome from FDA meeting on GENUINE trial of ublituximab

APBA3 and MCF2 gene methylation status to predict psychotherapy response in BPD

Pembrolizumab shows activity in phase II study in thymic epithelial tumors

Bayer submits marketing authorization application for BAY-94-9027 in Japan

Preclinical and clinical results presented for poziotinib in the treatment of NSCLC

Charleston Laboratories resubmits CL-108 NDA

Biosimilar GP-2017 shows efficacy similar to adalimumab in psoriasis patients

Xenon Pharmaceuticals begins phase I study of XEN-1101

Amneal Pharmaceuticals and Impax Laboratories announce merger

Takeda and HemoShear partner to discover and develop novel therapeutics for liver diseases

Teva submits BLA in U.S. for fremanezumab

Promentis studies safety of SXC-2023 in healthy volunteers in new phase I trial

Ignyta's entrectinib obtains PRIME designation from EMA

FDA clears Incysus's IND for gamma-delta T-cell immunotherapy

Merck KGaA presents novel cyclophilin inhibitors

Mutabilis joins ENABLE project

ProMIS Neurosciences' AD candidate selectively binds to amyloid beta oligomers

Gemini Therapeutics completes series A financing

ACY-241 in combination with nivolumab shows antitumoral activity in refractory NSCLC

Mitsubishi Tanabe Pharma identifies new CYP450 11B2 inhibitors

Tonix Pharmaceuticals gives update on Tonmya CMC guidance meeting with FDA

Novel griseofulvin derivatives discovered by Daiichi Sankyo

Acticor Biotech reaches agreement on phase I study of ACT-107

Cue Biopharma describes novel 4-1BBL variant immunomodulatory polypeptides

New twist-related protein 1 vaccines patented by Asahikawa Medical University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Sex differences shape gene activity across the human brain
BioWorld
Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
Gilead Sciences patents new GTPase KRAS G12D inhibitors
BioWorld Science
Gilead Sciences Inc. has disclosed new GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.